Sign up to get updates from us
It’s the circle of life: the cell cycle is a molecular merry-go-round for the propagation of all cells, including tumor cells. This process is regulated by cyclin-dependent kinases (CDKs), and CDK inhibition has long been a goal of drug developers; however, until very recently, toxicity has been an issue. Early clinical results suggest that Cyclacel Pharmaceuticals has potentially overcome that hurdle.
Tune in as Spiro Rombotis, CEO of Cyclacel Pharmaceuticals, describes Cyclacel’s Phase 1/2 studies with its two clinical stage molecules, including lead asset fadraciclib, a CDK2/9 inhibitor, in patients with solid cancers and hematological malignancies.
